Literature DB >> 7137396

Intensive treatment with haloperidol of treatment-resistant chronic schizophrenic patients.

L E Hollister, D Y Kim.   

Abstract

The authors treated 11 treatment-resistant schizophrenic patients with steadily increasing doses of haloperidol to determine the therapeutic range of plasma concentrations in such patients. Six patients responded, usually within a few weeks of treatment and at doses of 50 mg/day or less; plasma concentrations ranged between 17 and 42 ng/ml. Five patients were unresponsive, despite treatment for 13-22 weeks, doses of haloperidol of 180-270 mg/day, and plasma concentrations of 51-225 ng/ml. Doses greater than 150 mg/day appear unnecessary, because lesser doses generally provide plasma concentrations of 20-50 ng/ml. Failure to respond within 2 months of reaching such doses or plasma concentrations augurs for continued lack of response.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7137396     DOI: 10.1176/ajp.139.11.1466

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  5 in total

Review 1.  The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia.

Authors:  S Ulrich; C Wurthmann; M Brosz; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1998-03       Impact factor: 6.447

2.  Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance.

Authors:  M W Jann; S R Saklad; L Ereshefsky; A L Richards; C A Harrington; C M Davis
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

Review 3.  Clinical pharmacokinetics of the depot antipsychotics.

Authors:  M W Jann; L Ereshefsky; S R Saklad
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

4.  Plasma levels of fluphenazine and prolactin in psychiatric patients.

Authors:  T Kitamura; D A McGovern; N W Imlah; D Wiles; A A Schiff
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1988-09

Review 5.  The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychoses: a review.

Authors:  C Simhandl; K Meszaros
Journal:  J Psychiatry Neurosci       Date:  1992-03       Impact factor: 6.186

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.